Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

BACKGROUND: Patients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-line pembrolizumab in patients with advanced NSCLC...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Immunother Cancer
Main Authors: Alessi, Joao V, Ricciuti, Biagio, Jiménez-Aguilar, Elizabeth, Hong, Fangxin, Wei, Zihan, Nishino, Mizuki, Plodkowski, Andrew J, Sawan, Peter, Luo, Jia, Rizvi, Hira, Carter, Brett W, Heymach, John V, Altan, Mehmet, Hellmann, Matthew, Awad, Mark
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2020
נושאים:
Clinical/Translational Cancer Immunotherapy
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7406027/
https://ncbi.nlm.nih.gov/pubmed/32753547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001007
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים